HELIO ELKIS
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Psiquiatria, Faculdade de Medicina - Docente
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
88 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 88
bookPart Tratamento da esquizofrenia(2021) LOUZã, Mário Rodrigues; KAYO, Monica; VIZZOTTO, Adriana Dias Barbosa; MELZER-RIBEIRO, Débora Luciana; SARNO, Elaine Scapaticio Di; OLIVEIRA, Graça Maria Ramos de; NAPOLITANO, Isabel Cristina; GOMES, Mônica Lopes; ELKIS, HelioconferenceObject MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA(2018) HIGUCHI, Cinthia; COGO-MOREIRA, Hugo; BERTOLUCCI, Bruno; CORRELL, Christoph U.; NOTO, Cristiano; CORDEIRO, Quirino; FREITAS, Rosana; ELKIS, Helio; BELANGERO, Sintia I.; BRESSAN, Rodrigo A.; GADELHA, AryconferenceObject EFFICACY AND SAFETY OF TRANSCRANIAL DIRECT CURRENT STIMULATION FOR TREATING NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: THE FOLLOW-UP PHASE(2020) VALIENGO, Leandro; SERPA, Mauricio; ELKIS, Helio; BILT, Martinus Van de; LACERDA, Acioly; GATTAZ, Wagner; BRUNONI, AndreconferenceObject COMPARISON OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FACTOR STRUCTURE IN PATIENTS WITH REFRACTORY VERSUS NON REFRACTORY SCHIZOPHRENIA(2015) FREITAS, Rosana Ramos; VIZZOTTO, Adriana Dias Barbosa; AVRICHIR, Belquiz; SCENES, Silvia; SA JUNIOR, Antonio Reis de; SANTOS, Bernardo Pereira; LOUZA NETO, Mario Rodrigues; ELKIS, Helio- Meta-analyses of cavum septum pellucidum in mood disorders in comparison with healthy controls or schizophrenia(2018) BERALDI, Gabriel H.; PRADO, Kelly S.; AMANN, Benedikt L.; RADUA, Joaquim; FRIEDMAN, Lee; ELKIS, HelioThe cavum septum pellucidum (CSP) is a neurodevelopmental abnormality significantly more prevalent in subjects with schizophrenia (SCZ) than in healthy controls (HC). Using meta-analyses, we tested the hypotheses whether CSP would be more frequent in subjects with mood disorders when compared with HC or SCZ. We performed a search in MEDLINE and EMBASE followed by 10 meta-analyses of magnetic resonance imaging studies which examined the association of CSP in bipolar disorders (BD), major depressive disorder (MDD) or mood disorders (MD; considering MDD and BD combined) with either HC or SCZ. Nine studies were included, comprising 692 cases (363 with BD, 182 with MDD and 147 with MD), 463 with SCZ and 630 HC. CSP of any size was significantly associated with BD (OR = 2.07, 95% CI: 1.48-2.90) when compared with HC. Large CSP showed a trend to be associated with BD when compared with HC, but the association was not statistically significant (OR = 1.92, 95% CI 0.64-5.78). Large CSP was significantly associated with subjects with SCZ when compared with subjects with MD (OR = 0.57, 95% CI: 0.36-0.92). There was no association between CSP and MDD in comparison to HC or subjects with SCZ. Cortical structures are known to be altered in mood disorders. The present metanalysis found that certain midline brain abnormalities, such as CSP, are also associated with BD. (c) 2018 Published by Elsevier B.V.
- ECT versus Sham for clozapine-resistant schizophrenia: A secondary analysis of a pilot study based on PANSS-30 individual items(2020) MELZER-RIBEIRO, Debora Luciana; GRILLI-TISSOT, Maria Cristina Ribeiro; ELKIS, Helio
- RANDOMIZED AND CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF OCCUPATIONAL THERAPY IN THE REHABILITATION OF EXECUTIVE FUNCTIONS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA(2019) VIZZOTTO, Adriana; CELESTINO, Diego; BUCHAIN, Patricia; OLIVEIRA, Alexandra; OLIVEIRA, Graca; SARNO, Elaine Di; NAPOLITANO, Isabel; ELKIS, Helio
- Efficacy and Moderators of Cognitive Behavioural Therapy for Psychosis Versus Other Psychological Interventions: An Individual-Participant Data Meta-Analysis(2020) TURNER, David T.; REIJNDERS, Mirjam; GAAG, Mark van der; KARYOTAKI, Eirini; VALMAGGIA, Lucia R.; MORITZ, Steffen; LECOMTE, Tania; TURKINGTON, Douglas; PENADES, Rafael; ELKIS, Helio; CATHER, Corinne; SHAWYER, Frances; O'CONNOR, Kieron; LI, Zhan-Jiang; BARRETTO, Eliza Martha de Paiva; CUIJPERS, PimBackground Study-level meta-analyses have demonstrated the efficacy of cognitive-behavioural therapy for psychosis (CBTp). Limitations of conventional meta-analysis may be addressed using individual-participant-data (IPD). We aimed to determine a) whether results from IPD were consistent with study-level meta-analyses and b) whether demographic and clinical characteristics moderate treatment outcome. Methods We systematically searched PubMed, Embase, PsychInfo and CENTRAL. Authors of RCTs comparing CBTp with other psychological interventions were contacted to obtain original databases. Hierarchical mixed effects models were used to examine efficacy for psychotic symptoms. Patient characteristics were investigated as moderators of symptoms at post-treatment. Sensitivity analyses were conducted for risk of bias, treatment format and study characteristics. Results We included 14 of 23 eligible RCTs in IPD meta-analyses including 898 patients. Ten RCTs minimised risk of bias. There was no significant difference in efficacy between RCTs providing IPD and those not (p >0.05). CBTp was superior vs. other interventions for total psychotic symptoms and PANSS general symptoms. No demographic or clinical characteristics were robustly demonstrated as moderators of positive, negative, general or total psychotic symptoms at post-treatment. Sensitivity analyses demonstrated that number of sessions moderated the impact of treatment assignment (CBTp or other therapies) on total psychotic symptoms (p = 0.02). Conclusions IPD suggest that patient characteristics, including severity of psychotic symptoms, do not significantly influence treatment outcome in psychological interventions for psychosis while investing in sufficient dosage of CBTp is important. IPD provide roughly equivalent efficacy estimates to study-level data although significant benefit was not replicated for positive symptoms. We encourage authors to ensure IPD is accessible for future research.
- Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial(2021) BULUBAS, Lucia; GOERIGK, Stephan; GOMES, July S.; BREM, Anna-Katharine; CARVALHO, Juliana B.; PINTO, Bianca S.; ELKIS, Helio; GATTAZ, Wagner F.; PADBERG, Frank; BRUNONI, Andre R.; VALIENGO, LeandroCognitive deficits and negative symptoms in schizophrenia are associated with poor functional outcomes and limited in terms of treatment. The Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) trial has shown efficacy of transcranial direct current stimulation (tDCS) for improving negative symptoms. In this secondary analysis, we investigate its effects on cognitive performance. In STARTS, a double-blinded, sham controlled, randomized clinical trial, patients were treated with twice-daily, 20-min, 2-mA fronto-temporal tDCS over 5 days or sham-tDCS. In 90 patients, we evaluated the cognitive performance up to 12 weeks post-treatment. We found that active-tDCS showed no beneficial effects over sham-tDCS in any of the tests. Based on a 5-factor cognitive model, improvements of executive functions and delayed memory were observed in favor of shamtDCS. Overall, the applied active-tDCS protocol, primarily designed to improve negative symptoms, did not promote cognitive improvement. We discuss possible protocol modification potentially required to increase tDCS effects on cognition. ClinicalTrials.gov identifier: NCT02535676
- Treatment of Negative Symptoms of Schizophrenia With tDCS (Transcranial Direct Current Stimulation): A Randomized, Sham-Controlled, Double-Blinded Clinical Trial(2018) VALIENGO, Leandro; BILT, Martinus Theodorus van de; SERPA, Mauricio; GORDON, Pedro; HELKIS, Helio; GATTAZ, Wagner Farid; LACERDA, Acioly; BRUNONI, Andre